198 related articles for article (PubMed ID: 2823089)
1. Covalent labeling of mu opioid binding site by [3H]beta-funaltrexamine.
Liu-Chen LY; Phillips CA
Mol Pharmacol; 1987 Sep; 32(3):321-9. PubMed ID: 2823089
[TBL] [Abstract][Full Text] [Related]
2. Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
Liu-Chen LY; Chen C; Phillips CA
Mol Pharmacol; 1993 Oct; 44(4):749-56. PubMed ID: 8232225
[TBL] [Abstract][Full Text] [Related]
3. Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor.
Liu-Chen LY; Li SX; Tallarida RJ
Mol Pharmacol; 1990 Feb; 37(2):243-50. PubMed ID: 2154672
[TBL] [Abstract][Full Text] [Related]
4. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
[TBL] [Abstract][Full Text] [Related]
5. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
Tam SW; Liu-Chen LY
J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
[TBL] [Abstract][Full Text] [Related]
6. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
7. Opioid receptor binding characteristics of the non-equilibrium mu antagonist, beta-funaltrexamine (beta-FNA).
Ward SJ; Fries DS; Larson DL; Portoghese PS; Takemori AE
Eur J Pharmacol; 1985 Jan; 107(3):323-30. PubMed ID: 2984010
[TBL] [Abstract][Full Text] [Related]
8. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
J Pharmacol Exp Ther; 1988 Nov; 247(2):405-16. PubMed ID: 2846819
[TBL] [Abstract][Full Text] [Related]
9. Cross-linking of human [125I]beta-endorphin to opioid receptors in rat striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor complex.
Schoffelmeer AN; Yao YH; Gioannini TL; Hiller JM; Ofri D; Roques BP; Simon EJ
J Pharmacol Exp Ther; 1990 Apr; 253(1):419-26. PubMed ID: 2158552
[TBL] [Abstract][Full Text] [Related]
10. Characterization of irreversible binding of beta-funaltrexamine to the cloned rat mu opioid receptor.
Chen C; Xue JC; Zhu J; Chen YW; Kunapuli S; Kim de Riel J; Yu L; Liu-Chen LY
J Biol Chem; 1995 Jul; 270(30):17866-70. PubMed ID: 7629089
[TBL] [Abstract][Full Text] [Related]
11. Affinity labeling of mu and kappa receptors with naloxone benzoylhydrazone.
Standifer KM; Murthy LR; Kinouchi K; Steele L; Pasternak GW
Mol Pharmacol; 1991 Mar; 39(3):290-8. PubMed ID: 1848652
[TBL] [Abstract][Full Text] [Related]
12. Autoradiographic study of irreversible binding of [3H]beta-funaltrexamine to opioid receptors in the rat forebrain: comparison with mu and delta receptor distribution.
Liu-Chen LY; Li SX; Lewis ME
Brain Res; 1991 Mar; 544(2):235-42. PubMed ID: 1645609
[TBL] [Abstract][Full Text] [Related]
13. Affinity labeling of mu opioid receptors by sulfhydryl alkylating derivatives of morphine and morphinone.
Bidlack JM; Frey DK; Kaplan RA; Seyed-Mozaffari A; Archer S
Mol Pharmacol; 1990 Jan; 37(1):50-9. PubMed ID: 1688995
[TBL] [Abstract][Full Text] [Related]
14. Kinetic studies on binding of [3H] beta-funaltrexamine ([3H] beta-FNA) to mu opioid receptors.
Liu-Chen LY; Li S; Holowecky O; Tallarida RJ
Prog Clin Biol Res; 1990; 328():57-60. PubMed ID: 2154818
[No Abstract] [Full Text] [Related]
15. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
16. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
Puttfarcken PS; Werling LL; Cox BM
Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
[TBL] [Abstract][Full Text] [Related]
17. Solubilization and preliminary characterization of mu and kappa opiate receptor subtypes from rat brain.
Chow T; Zukin RS
Mol Pharmacol; 1983 Sep; 24(2):203-12. PubMed ID: 6310362
[TBL] [Abstract][Full Text] [Related]
18. Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.
Liu-Chen LY; Li SX; Wheeler-Aceto H; Cowan A
Eur J Pharmacol; 1991 Oct; 203(2):195-202. PubMed ID: 1666046
[TBL] [Abstract][Full Text] [Related]
19. Alkylation of mu opioid receptors by beta-funaltrexamine in vivo: comparison of the effects on in situ binding and heroin self-administration in rats.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1995 Mar; 272(3):1135-40. PubMed ID: 7891326
[TBL] [Abstract][Full Text] [Related]
20. Adrenal medullary opiate receptors. Pharmacological characterization in bovine adrenal medulla and a human pheochromocytoma.
Castanas E; Giraud P; Audigier Y; Drissi R; Boudouresque F; Conte-Devolx B; Oliver C
Mol Pharmacol; 1984 Jan; 25(1):38-45. PubMed ID: 6323951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
